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imaging diagnostics are top cost drivers of 
cancer medical care [5,6].
During recent decades, substantial rese-
arch and effort has been invested into deve-
lopment of monoclonal antibodies (mAbs) as 
novel, high profile pharmacological appro-
ach in cancer treatment [7]. Industrial pro-
duction costs of mAbs, as well as in many 
other branches of pharmaceutical research 
and development (R&D) will likely decrease 
over time [8]. Domination of different mAbs 
within top blockbuster drug lists, gives us a 
hint on the vital meaning of these agents to 
the pharmaceutical industry profits worldwi-
de [9,10].
Conventional cancer treatment protocols 
were compared to these cutting edge medical 
technologies. Some of them have undergone 
assessment in terms of evidence on their ef-
fectiveness and safety conducted by acade-
mia, governmental bodies and national drug 
agencies [11]. Each society has the interest to 
provide access to these medicines to most pe-
ople who need it, among whom high clinical 
ECONOMIC BURDEN OF CANCER 
AND THE ROLE OF TARGETED 
ONCOLOGY PHARMACEUTICALS
One of the core determinants of global he-
alth is providing access and affordability 
of evidence-based care for major diseases. 
Health care needs and pharmaceutical spen-
ding growth in Europe continues to outpace 
overall economy growth due to population 
aging of nations and scientific innovation in 
medicine [1]. Among “prosperity diseases” 
cancer bears particular epidemiological and 
financial burden due its prevalence, clinical 
evolution, poor prognosis and long term [2]. 
Malignant disorders decrease significantly 
life expectancy and its quality, affect pa-
tient’s working ability and therefore threatens 
overall economic productivity of the society 
[3]. Cancer is ranked among top five illnesses 
according to their economic burden, among 
all industrial nations of northern hemisphe-
re [4]. Besides pharmaceuticals and surgical 
procedures, some recent findings from this 
region indicate that radiation therapy and 
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ABSTRACT
Monoclonal antibodies applied in clinical oncology present a therapeutic promise for many patients with cancer. Neverthe-
less these expensive protocols are associated with extremely high acquisition and administration costs. The issue of soci-
etal affordability of such treatment options is particularly at stake among middle income European economies. Medicines 
Agency of Serbia issues regular annual reports on public expenditure on pharmaceuticals since 2004. According to these 
official data total public expenditure on drugs doubled from 2004-2012 (from € 339,279,304 to € 742,013,976). During 
the same nine years public expenditure on antineoplastic pharmaceuticals was rising at much faster pace, approximately 
five times from € 10,297,616 in 2004 to € 51,223,474 in 2012. Absolutely record growth belongs to the value of turnover 
of monoclonal antibodies indicated in diverse malignancies. These costs became almost twenty times higher in 2012 com-
pared to 2004 (€ 19,687,454 towards € 1,033,313 in the past). National pharmaceutical expenditure trend projections in this 
country show strong recovery in 2012 after severe blow to the overall health care market imposed by the worldwide crisis. 
Universal health insurance coverage and sustainable health care financing provision will remain difficult issues for Balkan 
economies in years to come. Although monoclonal antibodies exhibit undisputed therapeutic efficiency in certain malignant 
disorders, cost-effectiveness estimates must be taken into consideration by policy makers deciding on reimbursement.
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benefit is expected. There is still huge diver-
sity in national policies towards mAbs reim-
bursement in the EU, regardless of EMEA’s 
recommendations. Therefore access to targe-
ted cancer immunotherapies to the citizens is 
still very much uneven across Europe [11]. 
In spite of proved clinical efficiency in many 
oncological indications due to difficult ac-
quisition of such expensive agents, issues of 
reimbursement and affordability remain cru-
cial [12].
This contribution intent was to provide in-
sight into the local expenditure trends of mo-
noclonal antibodies applied in clinical onco-
logy. Such overview through the past decade 
in the largest country of the Western Balkans 
could be a picturesque example of what is 
happening in the broader Eastern European 
region. So far there is substantial knowled-
ge gap on this issue in Serbia and surroun-
ding countries. Unlike in many high income 
countries [13], there are few economic eva-
luations of mAbs based treatment protocols 
in published literature on Eastern European 
region [14,15].
PECULIARITY OF THE 
WESTERN BALKANS REGION
Eastern Europe and the Balkans region be-
long to the quite a different healthcare milieu 
comparing to the developed Western eco-
nomies. Most countries have inherited from 
past socialist model of medical care funding 
and provision [16]. Lower medical labour 
wages mostly shape the landscape of service 
provision. It should be emphasized that drug 
acquisition costs follow global market pri-
cing and remain only slightly lower than in 
the old pre-2004 EU members [17]. Electro-
nic patient registries development still has to 
make bold steps ahead. Region is gradually 
succeeding to create more reliable statistics 
on morbidity and mortality - more precise 
diagnostics is being evidenced, more decea-
sed are submitted to autopsy. Based on the-
se trends, more reliable future estimates and 
planning shall be possible [18].
Registry for Serbian cancer population was 
established in 1970 on the basis of statistical 
research of interest for the Republic of Ser-
bia. According to the last available edition 
of Health Statistical Yearbook of Republic 
of Serbia, incidence rate of all malignant tu-
mours in the country was 26,663 cases while 
15,042 patients have deceased in 2009 [19]. 
Epidemiological situation on cancer in Serbia 
is particularly difficult and serious compared 
to the EU average, because total incidence 
rates increased over 2.5 times while cancer-
specific mortality rates increased approxima-
tely 1.5 times in only two decades from 1990 
to 2010 [20]. There are probably several un-
derlying reasons for such morbidity. Most 
frequently cited medical causes are proximi-
ty of Chernobyl [21], ecological consequen-
ces of 1990s military conflicts [22], post-war 
syndromes and unhealthy life style [23].    
CURRENT SITUATION ON MABS 
AVAILABILITY AND ACCESS 
IN SERBIAN ONCOLOGY
Out of some 15 different generic compounds 
among monoclonal antibodies used to tre-
at malignant disorders according to current 
WHO selection under ATC code L01XC 
[24] there are six drugs with currently po-
sitive marketing approval gained from the 
Medicines and Medicinal Device Agency of 
Serbia [25] in 2014. These are: pertuzumab, 
panitumumab, bevacizumab, cetuximab, 
trastuzumab and rituximab. Choice of these 
medicines varied slightly over time period 
observed (2004-2012) while some manu-
facturers were acquiring licences and others 
loosing them. Although these drugs are mar-
keted for a wider indication field, Republican 
Health Insurance Fund of Serbia has impo-
sed reimbursement criteria with few strictly 
defined malignancies for each one of these 
drugs. It is single, central, state-owned, Ea-
stern European-type fund in charge of most 
public health care facing difficult challenges 
in providing sustainable financing in recent 
years, mostly due to global economic crisis 
[17]. An example of Fund’s restrictive policy 
is acknowledgment only of those drug acqui-
sition costs which incurred during rituximab 
or cetuximab treatment of non-Hodgkin lym-
phoma; bevacizumab or cetuximab treatment 
of colorectal carcinoma and trastuzumab or 
rituximab treatment of breast cancer. These 
three malignancy groups were of particularly 
high relevance being among top four most 
expensive cancers to treat in the US in 2004, 
due to mAbs utilization [26]. Mabs based 
oncology protocols are administered only 
in few recognized tertiary university hospi-
tals throughout the country. While keeping 
in mind middle income Western Balkans 
setting we should be aware that out of these 
indications, biological antineoplastics remain 
virtually unaffordable to the ordinary citizens 
if they have to be acquired via out-of-pocket 
expense [27].
Recently finished pioneering retrospecti-
ve study on cancer economics reported first 
extensive data on costs of initial medical care 
of newly diagnosed cancer with mean value 
of € 6,949 (SD € 36,414) per patient within 
first six months since diagnosis [28]. These 
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data were acquired on a broad sample of over 
1,200 patients with diverse ICD-10 diagno-
stic codes, stages and grades of disease. An 
excellent comparator to these data is provi-
ded by another ongoing local study focused 
on another prevalence-based sample of pa-
tients whose treatment protocols consisted of 
mAbs with adjuvant conventional cytostatic 
regimen. This study reported an average di-
rect cost of medical care of € 13,658 in the 
approximately four month’s long time hori-
zon [29]. One could easily notice the pattern 
of almost two and a half fold higher total 
costs of hospital care among mAbs treated 
patients when compared to the ordinary pa-
tients regardless of clinical background data 
in Serbian setting.
Serbian national medicines agency (ALIMS) 
issues regular yearly reports on public medi-
cines turnover and sales in the country. Ac-
cording to these reports total medicines re-
lated public expenditure grew twice from € 
339,279,304 in 2004 to €742,013,976 in 2012 
(Figure 1) [24]. In the same time public ex-
penditure on antineoplastic pharmaceuticals 
grew faster, approximately five times from € 
10,297,616 in 2004 to € 51,223,474 in 2012.
One decade ago, according to the Agency’s 
official release monoclonal antibodies ente-
red the market in a shy manner representing 
only the minor portion of overall oncology 
therapeutics expenditure. Since 2004 its bud-
Figure 1. Increase in total public drug expenditure compared to the growth 
of overall antineoplastics expenditure (Serbia 2004-2012). Source of data: 
Medicines and Medicinal Device Agency of the Republic of Serbia – ALIMS [24]
get share among total antineoplastic drug ac-
quisition costs was rising sharply and became 
by far the most dominant one already in 2006 
(see Figure 2). 
Recorded growth of market size in nine year 
term from € 1,033,313 (10.03 %) in 2004 up 
to the € 19,687,454 or 38.43 % in 2012. To-
Figure 2. Public expenditure trend 2004-2012 on antineoplastic agents in Serbia (official exchange rates of National Bank of Serbia in 
respective years 2004-2012 were applied). Source of data: Medicines and Medicinal Device Agency of the Republic of Serbia – ALIMS [24]
* ATC code group L01 expressed as volume of sales in Euro values
° ATC drug code groups’ clarification. ATC code group L01 encompasses: alkylating agents, antimetabolites, plant alkaloids and other natural 
products, cytotoxic antibiotics and related substances, other antineoplastic agents (L01X). The last subgroup further consists of platinum compounds, 
methylhydrazines, monoclonal antibodies, sensitizers used in photodynamic/radiation therapy, protein kinase inhibitors, other antineoplastic agents 
and combinations of antineoplastic agents
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tal oncology related drug acquisition costs in 
the public health care sector amounted from 
€ 10,297,616 in 2004 to € 51,223,474 in 2012 
respectively [24]. This means that the incre-
ase in total expenditure on antineoplastic 
pharmaceuticals was five times while incre-
ase in mAbs consumption was almost twenty 
times in terms of absolute value in only nine 
years time span. Mabs prescribing and con-
sumption financially clearly far outpace total 
oncological drug expenditure growth. These 
findings nationwide are in line with reported 
unit consumption of mAbs in a local univer-
sity clinic in Serbia [30].
Observing the data on public consumption 
and sales given on the graph 2 we can no-
tice strong rise in market demand and sales 
from 2004 up to the 2010 and then sudden 
drop in 2011 with strong recovery trend 
upwards in 2012, slightly overstepping 2010 
limit. This happened due to consequences of 
worldwide economic crisis in the region as 
well as due to transitional difficulties related 
to national health systems reforms from So-
viet to Western market oriented models [5]. 
Although the official data on drug sales for 
2013 are still lacking, according to our data 
for 2012 and most pharmaceutical market 
forecasts, steady recovery is to be expected 
in following years [31]. It should also be no-
ted that national drug agency of Serbia has 
insight only into public, state-owned hospi-
tals and pharmacists reported utilization of 
medicines. This is an important limitation 
in many therapeutic areas for interpreting 
data, because of lacking private sector sales 
which add substantial value to the market 
size. In case of biological drugs administe-
red in the specialist oncology clinics this 
is less relevant because these protocols are 
so far administered only in few key referral 
public university hospitals throughout the 
country [32].
CONCLUSIVE REMARKS
While total medicines related public expendi-
ture in Serbia 2004-2012 became approxima-
tely only twice higher, antineoplastic phar-
maceuticals expenditure grew five times. In 
the same period mAbs prescribing and con-
sumption value have overrun this trend with 
almost twenty times increase.
Regardless of evidence on clinical effecti-
veness, mAbs oncology protocols may have 
unbearable budget impact in some low and 
middle income national health systems [33]. 
Due to particularly decisive influence to the 
overall antineoplastics expenditure planning, 
mAbs prescribing must be firmly grounded 
in clinical guidelines as well as in cost-ef-
fectiveness estimates [34]. Previous studies 
have shown that it is possible to reshape cli-
nician’s prescribing behavior with evidence 
based guidelines [35]. Higher awareness of 
clinicians on cost limitations and necessity 
of prioritization in health care funding would 
provide wiser allocation of scarce resources 
and better access to the quality medical care 
to the citizens.
Another key strategy intended to control sky 
rocketing costs of mAbs in clinical oncology 
[36] was complex generic substitution policy 
such as the one promoted in Japan [37]. Ne-
vertheless, because of demanding technology 
of monoclonal antibodies production [38] ap-
pearance of generic mAbs is yet to be awai-
ted in the world market [39].
Third commonly applied policy pattern was 
noticed response of Serbian authorities to the 
difficulties of health care financing – intro-
duction of limitation criteria for mAbs reim-
bursement. In this scenario these medicines 
are administered only to the narrow selection 
of patients who are most likely to benefit 
from the treatment and/or least likely to ex-
perience serious adverse events [40].
An eeffort should be invested to exert pressu-
re on higher ranked officials in the Ministry of 
Health and National Health Insurance Fund 
to implement health economics tools into 
clinical practice. Evidence based resource 
allocation should be more systematically 
applied to the clinical decision making par-
ticularly in technologically most demanding 
and expensive branches of medicine [41]. For 
this purpose substantial efforts are needed to 
persuade decision makers emphasizing them 
the opportunities for long-term savings while 
preserving clinical benefit coming from these 
drugs.
We should never forget the key role of the-
se expensive targeted immunotherapies to 
the improved survival in many patients with 
diverse clinical entities of disease, stage 
and grade upon diagnosis [4]. Further R&D 
investment on highly specific biological 
agents has yet to bring hope to many patients 
with poor prognosis at the present level of 
knowledge [42]
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